Luca Malcovati

Active 1999–2025

141
Papers
30,798
Citations
83
h-index
129
i10-index

Citations

Citations per year for Luca Malcovati1989: 2 citations1996: 1 citations2000: 3 citations2004: 2 citations2005: 3 citations2006: 32 citations2007: 45 citations2008: 77 citations2009: 79 citations2010: 82 citations2011: 88 citations2012: 170 citations2013: 207 citations2014: 281 citations2015: 284 citations2016: 288 citations2017: 241 citations2018: 227 citations2019: 799 citations2020: 858 citations2021: 899 citations2022: 885 citations2023: 861 citations2024: 1,402 citations2025: 590 citations2026: 15 citations1990–1995: no citations, so these years are not shown1997–1999: no citations, so these years are not shown2001–2003: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,208 citing papers, 24.5% of this breakdownItaly: 761 citing papers, 8.4% of this breakdownGermany: 743 citing papers, 8.2% of this breakdownUnited Kingdom: 659 citing papers, 7.3% of this breakdownFrance: 536 citing papers, 6% of this breakdownSpain: 404 citing papers, 4.5% of this breakdownChina: 385 citing papers, 4.3% of this breakdownCanada: 288 citing papers, 3.2% of this breakdownNetherlands: 259 citing papers, 2.9% of this breakdownJapan: 246 citing papers, 2.7% of this breakdownSweden: 237 citing papers, 2.6% of this breakdownAustralia: 214 citing papers, 2.4% of this breakdown
0%24.5%Other 23%

Fields

  • Medicine73.8%
  • Biochemistry, Genetics and Molecular Biology20.9%
  • Immunology and Microbiology3.8%
  • Computer Science0.6%
  • Energy0.1%
  • Neuroscience0.1%
  • Other0.7%

Topics

  • Acute Myeloid Leukemia Research18.8%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment10.5%
  • Chronic Myeloid Leukemia Treatments3.5%
  • Cancer Genomics and Diagnostics3.3%
  • Hematopoietic Stem Cell Transplantation3.1%
  • RNA modifications and cancer3.1%
  • Other57.7%

Coauthors

All papers

Open in search
  1. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Richard A. Larson, Michelle M. Le Beau, Mignon L. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte M. Niemeyer, Olatoyosi Odenike, Seishi Ogawa, Alberto Órfão, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching‐Hon Pui, Jerald P. Radich, Andreas Reiter, Marı́a Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt‐Graeff, Akiko Shimamura, Jorge Sierra, Wendy Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei‐Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi - Blood 2022 cited by 2,693

  2. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Akifumi Takaori‐Kondo, Takayuki Ishikawa, Shigeru Chiba, Senji Kasahara, Yasushi Miyazaki, Agnès Viale, Kety Huberman, Pierre Fenaux, Monika Beličková, Michael R. Savona, Virginia M. Klimek, Fábio Pires de Souza Santos, Jacqueline Boultwood, Ιoannis Kotsianidis, Valeria Santini, Françesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Kazuma Ohyashiki, Carlo Finelli, Maria Teresa Voso, Lee‐Yung Shih, Michaëla Fontenay, Joop H. Jansen, José Cervera, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Luca Malcovati, Mario Cazzola, Seishi Ogawa, Eva Hellström‐Lindberg, Elli Papaemmanuil - NEJM Evidence 2022 cited by 813

  3. Revised International Prognostic Scoring System for Myelodysplastic Syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Teresa Vallespı́, Arjan A. van de Loosdrecht, Ulrich Germing, Detlef Haase - Blood 2012 cited by 3,140

  4. Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis

    Authors: , , , , , , , , , , , , , , , , , , - NEJM Evidence 2023 cited by 295

  5. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jacqueline Boultwood, Fábio Pires de Souza Santos, Julie Schanz, Senji Kasahara, Takayuki Ishikawa, Hisashi Tsurumi, Akifumi Takaori‐Kondo, Toru Kiguchi, Chantana Polprasert, John M. Bennett, Virginia M. Klimek, Michael R. Savona, Monika Beličková, Christina Ganster, Laura Palomo, Guillermo Sanz, Lionel Adès, Matteo Giovanni Della Porta, Harold K. Elias, Alexandra Smith, Yesenia Werner, Minal Patel, Agnès Viale, Katelynd Vanness, Donna Neuberg, Kristen E. Stevenson, Kamal Menghrajani, Kelly L. Bolton, Pierre Fenaux, Andrea Pellagatti, Uwe Platzbecker, Michael Heuser, Peter Valent, Shigeru Chiba, Yasushi Miyazaki, Carlo Finelli, Maria Teresa Voso, Lee‐Yung Shih, Michaëla Fontenay, Joop H. Jansen, José Cervera, Yoshiko Atsuta, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Mario Cazzola, Eva Hellström-Lindberg, Seishi Ogawa, Elli Papaemmanuil - Nature Medicine 2020 cited by 636

  6. Clinical and biological implications of driver mutations in myelodysplastic syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anthony R. Green, Jacqueline Boultwood, Paresh Vyas, Eva Hellström‐Lindberg, David Bowen, Mario Cazzola, Michael R. Stratton, Peter J. Campbell - Blood 2013 cited by 1,832

  7. SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , E. Joanna Baxter, J Score, Anna Gallì, Matteo Giovanni Della Porta, Erica Travaglino, Michael J. Groves, Sudhir Tauro, Nikhil C. Munshi, Kristina Anderson, Adel K. El‐Naggar, Andrej Fischer, Ville Mustonen, Alan J. Warren, Nicholas C.P. Cross, Anthony R. Green, P. Andrew Futreal, Michael R. Stratton, Peter J. Campbell - New England Journal of Medicine 2011 cited by 1,216

  8. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Attilio Orazi, Elli Papaemmanuil, Andreas Reiter, David M. Ross, Michael R. Savona, Akiko Shimamura, Radek C. Skoda, Françesc Solé, Richard M. Stone, Ayalew Tefferi, Matthew J. Walter, David Wu, Benjamin L. Ebert, Mario Cazzola - Blood 2022 cited by 208

  9. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 cited by 1,972

  10. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Detlef Haase, Heinz Tüchler, Peter L. Greenberg, Seishi Ogawa, Eva Hellström‐Lindberg, Mario Cazzola - Blood 2020 cited by 293

  11. Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome

    Authors: , , , , , , , , , , , , , , , , , - Nature Cell Biology 2022 cited by 130

  12. Multiparameter prediction of myeloid neoplasia risk

    Authors: , , , , , , , , , , , , , - Nature Genetics 2023 cited by 108

  13. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2017 cited by 376

  14. Germ lineDDX41mutations define a unique subtype of myeloid neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Shigeru Chiba, Hisashi Tsurumi, Senji Kasahara, Carsten Müller‐Tidow, Akifumi Takaori‐Kondo, Kazuma Ohyashiki, Toru Kiguchi, Fumihiko Matsuda, Joop H. Jansen, Chantana Polprasert, Piers Blombery, Yoichiro Kamatani, Satoru Miyano, Luca Malcovati, Torsten Haferlach, Michiaki Kubo, Mario Cazzola, Austin Kulasekararaj, Lucy A. Godley, Jaroslaw P. Maciejewski, Seishi Ogawa - Blood 2022 cited by 143

  15. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michaëla Fontenay, Olivier Kosmider, Michal Bar‐Natan, David P. Steensma, Richard M. Stone, Michael Heuser, Felicitas Thol, Mario Cazzola, Luca Malcovati, Aly Karsan, Christina Ganster, Eva Hellström‐Lindberg, Jacqueline Boultwood, Andrea Pellagatti, Valeria Santini, Lynn Quek, Paresh Vyas, Heinz Tüchler, Peter L. Greenberg, Rafael Bejar - Leukemia 2019 cited by 259

  16. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Phillip Scheinberg, Reinhard Stauder, Arjan A. van de Loosdrecht, Andrew H. Wei, Mikkael A. Sekeres, Pierre Fenaux - Blood 2023 cited by 92

  17. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

    Authors: , , , , , , , , , , , , , , , , , , , , , - Blood 2013 cited by 667

  18. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Blood 2016 cited by 361

  19. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

    Authors: , , , , , , , , , , , , , , , , , , , , , - Blood 2015 cited by 428

  20. Clinical significance of somatic mutation in unexplained blood cytopenia

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood 2017 cited by 469

  21. Relationship between clone metrics and clinical outcome in clonal cytopenia

    Authors: , , , , , , , , , , , , , , , , , , , - Blood 2021 cited by 103

  22. Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia

    Authors: , , , , , , , , , , , , , , , , , - Nature Communications 2018 cited by 184

  23. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matteo Della Porta, Kety Huberman, Pierre Fenaux, Monika Beličková, Michael R. Savona, Virginia M. Klimek, Fábio Pires de Souza Santos, Jacqueline Boultwood, Ιoannis Kotsianidis, Valeria Santini, Françesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee‐Yung Shih, Seishi Ogawa, Michaëla Fontenay, Joop H. Jansen, José Cervera, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, David B. Beck, Eva Hellström‐Lindberg, Elli Papaemmanuil - Blood 2024 cited by 49

  24. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

    Authors: , , , , , , , , , , , , , , , - Blood 2018 cited by 178